Acasă › Carcinom urotelial (cu celule de tranziție) › Tennessee › Nashville
Studii clinice pentru Carcinom urotelial (cu celule de tranziție) în Nashville, TN
23 studii pentru Carcinom urotelial (cu celule de tranziție) caută participanți în și în jurul orașului Nashville (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1
- Tennessee Oncology, Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
În curs de recrutareFaza 1
- Exelixis Clinical Site #3, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
În curs de recrutareFaza 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
În curs de recrutareFaza 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
În curs de recrutareFaza 3
- SCRI Oncology Partners, Nashville
DBC-664 in Adult Patients With Solid Tumors
În curs de recrutareFaza 1
- SCRI Oncology Partners, Nashville
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
În curs de recrutareStudiu observațional
- Vanderbilt University Medical Center, Nashville
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
În curs de recrutareFaza 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology, Nashville
- și încă 9
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
În curs de recrutareFaza 1
- Sarah Cannon Research Institute, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
În curs de recrutareFaza 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
În curs de recrutareFaza 3
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
În curs de recrutareFaza 2/3
- Research Site, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
În curs de recrutareFaza 1
- Sarah Cannon Research Institute, Nashville
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
În curs de recrutareFaza 1/2
- Tennessee Oncology, Nashville
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
În curs de recrutareFaza 2/3
- Research Site, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
În curs de recrutareFaza 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
În curs de recrutareFaza 1/2
- SCRI Oncology Partners, Nashville
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
În curs de recrutareFaza 3
- Research Site, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
În curs de recrutareFaza 2
- SCRI Oncology Partners, Nashville
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
În curs de recrutare
- Vanderbilt University Medical Center, Nashville
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
În curs de recrutareFaza 2
- Site 02-007 - Urology Associates, P. C, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Nashville
Studii pentru Carcinom urotelial (cu celule de tranziție) în alte orașe
- New York City, NY22 studii
- Houston, TX19 studii
- Dallas, TX18 studii
- Edison, NJ18 studii
- Los Angeles, CA17 studii
- Queens, NY15 studii
- Chicago, IL14 studii
- Arlington, VA12 studii
- Boston, MA11 studii
- San Antonio, TX11 studii
- Austin, TX10 studii
- Orange, CA10 studii
Alte studii în Nashville
- Cancer pulmonar cu celule non-pătrate97 studii
- Cancer de sân81 studii
- Cancer metastatic70 studii
- Cancer colorectal69 studii
- Cancer (toate tipurile)65 studii
- Cancer ovarian49 studii
- Cancer de prostată43 studii
- Cancer pulmonar40 studii
- Carcinom cu celule scuamoase de cap și gât39 studii
- Cancer pancreatic39 studii
- Cancer endometrial38 studii
- Melanom33 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.